MI-LINEAGE
Lineage, Inc. (the “Company”) today announced that it has publicly filed a registration statement on Form S-11 with the U.S. Securities and Exchange Commission (the “SEC”) to sell shares of its common stock in an underwritten initial public offering.
The timing, number of shares that may be offered and the price range for the proposed offering have not yet been determined. The Company intends to apply to list its common stock on the Nasdaq Global Select Market under the ticker symbol "LINE." The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan and Wells Fargo Securities are acting as joint lead book-running managers for the proposed offering. RBC Capital Markets, LLC, Rabo Securities USA, Inc., Scotia Capital (USA) Inc., UBS Securities LLC, Capital One Securities, Inc., Truist Securities, Inc., Evercore Group L.L.C., Robert W. Baird & Co. Incorporated, KeyBanc Capital Markets Inc., Mizuho Securities USA LLC, PNC Capital Markets LLC, Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., Piper Sandler & Co. and Regions Securities LLC are acting as joint book-running managers for the proposed offering. Blaylock Van, LLC, Cabrera Capital Markets LLC, C.L. King & Associates, Inc., Drexel Hamilton, LLC, Guzman & Company, Loop Capital Markets LLC, Roberts & Ryan Investments, Inc. and R. Seelaus & Co., LLC are acting as co-managers.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to this offering, when available, may be obtained from Morgan Stanley, Prospectus Department, 180 Varick Street, New York, New York 10014, or email: prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or email: prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; and Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.
About Lineage
Lineage, Inc. is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84.1 million square feet and 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage companies to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world.
Important Information
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
Certain statements contained in this press release, including statements relating to Lineage’s expectations regarding the commencement, completion, timing and size of its proposed public offering and listing, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage’s performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626669238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom